______________________ Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2024 RESULTS • Baxter third-quarter 2024 sales totaled $3.85 billion • Third-quarter total Baxter U.S. GAAP diluted earnings per share (EPS) were $0.27 ; adjusted total Baxter diluted EPS were $0.80 , exceeding the company's previously issued guidance • Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis , reflecting growth across all segments • Third ...

Baxter International Inc. (BAX) is scheduled to release third-quarter 2024 results on Nov. 8, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 3.03%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the consensus estimate for revenues is pegged at $3.84 billion, indicating an improvement o ...

In its upcoming report, Baxter International (BAX) is predicted by Wall Street analysts to post quarterly earnings of $0.78 per share, reflecting an increase of 14.7% compared to the same period last year. Revenues are forecasted to be $3.84 billion, representing a year-over-year increase of 3.6%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of ...

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earning ...

The time has finally come. On September 18th, the Federal Reserve slashed rates by 50 basis points. While this has been a pretty exciting time for markets, the question now becomes what works best post-rate cut? To answer thatI am an individual value investor pursuing a bachelor's degree in Finance at Florida State University with the goal of attaining my CFA. I have a distinct passion for equity research and fundamental analysis. Regarding my approach, I have been highly influenced by Tom Hayes, Founder, C ...

Core Viewpoint - Baxter International (BAX) is positioned for growth due to the demand for its essential medical products and ongoing transformational actions, despite facing inflationary pressures [1]. Company Performance - Baxter reported solid year-over-year growth in both earnings and revenues for the second quarter of 2024, with overall sales strong across product categories, except for a decline in Front Line Care due to the U.S. primary care market [3]. - Revenues from continued operations totaled $3.81 billion in the second quarter, reflecting a 3% increase on a reported basis and a 4% increase at constant currency [5]. Product Development and Transformational Actions - Recent product launches, including the Vest Advanced Pulmonary Experience (APX) System and the Helion Integrated Surgical System, are expected to contribute to top-line growth [4]. - The company has implemented a new simplified structure to enhance supply chain resilience and align with its manufacturing footprint, with updates expected in the third-quarter earnings call [4]. Divestitures and Financial Strategy - Baxter divested its BioPharma Solutions business for $4.25 billion in cash to focus on core operations and reduce interest expenses [4]. - In August, Baxter entered into an agreement to divest its Vantive Kidney Care segment for $3.8 billion, with plans to use the proceeds to reduce debt and improve operational efficiency [5]. Market Dynamics and Challenges - Despite recovery, Baxter faces ongoing pressure related to hospital admissions and procedural volumes, with supply chain disruptions impacting growth [6]. - The Asia-Pacific market contributes nearly 17% to Baxter's revenues, with significant growth opportunities in China, although challenging market dynamics may affect performance [6]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for 2024 revenues is $15.22 billion, indicating a 1.8% increase from the previous year [7]. - The consensus estimate for adjusted earnings per share (EPS) is $2.96, reflecting a 13.9% increase from the prior year, with a 1.7% improvement in estimates over the past 60 days [7].

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are ...

Baxter International, Inc. (BAX) announced the launch of its next-generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. Baxter received FDA 510(k) clearance for The Vest APX System in March 2024.The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort ...

Industry Overview - The Zacks Medical – Products industry is experiencing revenue growth driven by strong demand for surgeries, new product launches, and market expansion [1][2] - An early surge in demand for respiratory products is positively impacting sales [1] - Industry players are increasing product and service prices to manage higher costs, benefiting both top and bottom lines [1] Market Dynamics - U.S. hospitals are likely to increase budgets due to improving demand and lower interest rates, which may enhance medical product sales [2] - Supply-chain constraints, rising material costs, and labor shortages are ongoing challenges for the industry [2][3] - A decline in demand for COVID-19-related products is negatively affecting revenues, alongside a soft market in China [2] Key Players - Companies like Boston Scientific, Baxter International, Haemonetics, and Phibro Animal Health are adapting to changing consumer preferences and are seeing share price increases [2] - The industry is ranked 63 in the Zacks Industry Rank, placing it in the top 25% of over 250 Zacks industries, indicating positive near-term prospects [8] Performance Metrics - The industry has outperformed its own sector with a collective stock increase of 21.6%, compared to the Zacks Medical sector's growth of 12.3% [9] - The industry is currently trading at a forward P/E of 22.2X, slightly above the S&P 500's 21.8X and the sector's 23.3X [10] Technological Trends - The adoption of AI, medical mechatronics, and robotics is shaping the future of the medical products industry, particularly in minimally invasive surgeries [4][5] - 3D printing technology is revolutionizing the medical devices sector by enabling the production of complex biological structures [5] Demand Trends - The COVID-19 pandemic has led to increased global demand for diagnostic testing kits, shifting the focus towards rapid, point-of-care devices [6] - Emerging markets are showing strong demand for medical products due to rising medical awareness and economic growth [6] Company Highlights - **Boston Scientific**: Anticipates 13.5-14.5% net sales growth for the full year 2024, with a Zacks Rank of 2 [12][14] - **Baxter International**: Expects 3% sales growth for 2024, with a Zacks Rank of 2 [15][17] - **Haemonetics**: Forecasts 5-8% revenue growth for fiscal 2025, holding a Zacks Rank of 2 [18][19] - **Phibro Animal Health**: Projects a 19% CAGR in revenues from fiscal 2025-2027, despite facing regulatory challenges [20][21]